Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.78 |
| ▸ | PI4KA | P42356 | 2/20 | 0.75 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.75 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.75 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.75 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.73 |
| ▸ | DPP4 | P27487 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.73 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.73 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.73 |
| ▸ | GAPDH | P04406 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.73 |
| ▸ | STAT6 | P42226 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22027656 | 1.00 | GAA (0.78) | GAAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL28984635 | 1.00 | GAA (0.78) | GAAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL2585481 | 1.00 | GAA (0.78) | GAAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14565272 | 1.00 | GAA (0.78) | GAAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5472130 | 1.00 | GAA (0.78) | GAAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5471536 | 1.00 | GAA (0.78) | GAAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL23982184 | 1.00 | GAA (0.78) | GAAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5471540 | 1.00 | GAA (0.78) | GAAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL16351393 | 0.90 | GAA (0.81) | GAAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL2036682 | 0.90 | GAA (0.81) | GAAPI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3922637-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | Janssen Pharmaceutica NV (BE) | 2021-12-15 | — | — | EP | disclosed |
| US-20210095284-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | Janssen Biopharma, Inc. | 2021-04-01 | — | — | US | disclosed |
| US-20210040483-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | Janssen Biopharma, Inc. (US) | 2021-02-11 | — | — | US | disclosed |
| US-10793859-B2 | Modified oligonucleotides and methods of use | Janssen Biopharma, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| WO-2019175260-A2 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE IN TAUOPATHIES | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-19 | — | — | WO | disclosed |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-9771578-B2 | Phosphorous-linked oligomeric compounds and their use in gene modulation | IONIS PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160076031-A1 | PHOSPHOROUS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | METKINEN OY (FI) | 2007-03-22 | — | — | US | disclosed |
| US-20050042647-A1 | Phosphorous-linked oligomeric compounds and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2005-02-24 | — | — | US | disclosed |
| US-20040254358-A1 | Phosphorous-linked oligomeric compounds and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2004-12-16 | — | — | US | disclosed |
| US-20040171028-A1 | Phosphorous-linked oligomeric compounds and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
| JP-2001151793-A | 9-(2,3-ANHYDRO-β-D-LYXOFURANOSYL)-ADENINE DERIVATIVE | MITSUBISHI CHEMICALS CORP | 2001-06-05 | — | — | JP | disclosed |
| JP-2001151793-A | 9-(2,3-ANHYDRO-β-D-LYXOFURANOSYL)-ADENINE DERIVATIVE | MITSUBISHI CHEMICALS CORP | 2001-06-05 | — | — | JP | disclosed |
| US-5571799-A | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response | BASCO, LTD. (US) | 1996-11-05 | — | — | US | disclosed |
| EP-0305843-A2 | Antiviral agent | BAYER AG (DE) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793859-B2 | Modified oligonucleotides and methods of use | NSUN2, ADAR, POLM | GAA 1093/4885PI4KA 3020/4885PI4K2B 2745/4885 |
| US-20040171028-A1 | Phosphorous-linked oligomeric compounds and their use in gene modulation | RTCB, PHAX, RRBP1 | GAA 3392/4885PI4KA 1837/4885PI4K2B 1086/4885 |
| US-20210040483-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | GAA 1305/4885PI4KA 2899/4885PI4K2B 2642/4885 |
| US-20210095284-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | MAPT, PSEN2, NSUN2 | GAA 186/4885PI4KA 3467/4885PI4K2B 2698/4885 |
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | DUT, UNG, GALE | GAA 138/4885PI4KA 3568/4885PI4K2B 3607/4885 |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | GAA 1093/4885PI4KA 3020/4885PI4K2B 2745/4885 |
| US-20040254358-A1 | Phosphorous-linked oligomeric compounds and their use in gene modulation | RTCB, PHAX, RRBP1 | GAA 3392/4885PI4KA 1837/4885PI4K2B 1086/4885 |
| US-20050042647-A1 | Phosphorous-linked oligomeric compounds and their use in gene modulation | RTCB, PHAX, RRBP1 | GAA 3392/4885PI4KA 1837/4885PI4K2B 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.